Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease

Inclusion Criteria: 1. age 55 to 85 years; 2. should have a mild-to-moderate AD diagnosis (MMSE 10-26 inclusive); 3. should have evidence of elevated cortical amyloid by PET using florbetapir F18 (Amyvid) \[i.e. a positive scan\], assessed qualitatively according to the Amyvid product label. 4. if on anti-dementia treatment should be on stable treatment for at least 2 months (i.e. cholinesterase inhibitor and/or Memantine or Axona); 5. stable on all other medications for at least 30 days prior to screen; 6. should be fluent in English; 7. should be physically able to participate by medical history, clinical exam and tests; 8. should have a study partner to accompany them to scheduled visits. Exclusion Criteria: 1. clinically relevant arrhythmias; 2. a resting pulse less than 50; 3. active cancer other than non-melanoma skin cancers; 4. use of another investigatory drug within 2 months of screening; 5. significant stroke or head trauma by history or MRI; 6. contraindication for having a MRI; 7. diagnostic and Statistical Manual of Mental Disorders-IV criteria for a current major psychiatric disorder; 8. sensitivity to yeast or yeast products; 9. impaired kidney function as measured by a Glomerular Filtration Rate less than 60 milliliters/min; 10. preexisting fluid retention, pulmonary infiltrates, or congestive heart failure; 11. history of moderate-to-severe lung disease; 12. history of moderate-to-severe liver disease; 13. pregnant women, or any women who feel they are likely to become pregnant during the study; 14. prisoners.